CN Patent

CN112543646B — 一种抗pd-1抗体和法米替尼联合在制备治疗肿瘤的药物中的用途

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2023-11-14 · 3y expired

What this patent protects

本公开提供了一种抗PD‑1抗体和法米替尼联合在制备治疗肿瘤的药物中的用途。该技术方案毒性可控、可耐受，同时联合给药能够有效降低抗PD‑1抗体的不良反应，如反应性毛细血管增生症的发生。

USPTO Abstract

本公开提供了一种抗PD‑1抗体和法米替尼联合在制备治疗肿瘤的药物中的用途。该技术方案毒性可控、可耐受，同时联合给药能够有效降低抗PD‑1抗体的不良反应，如反应性毛细血管增生症的发生。

Drugs covered by this patent

Patent Metadata

Patent number
CN112543646B
Jurisdiction
CN
Classification
—
Expires
2023-11-14
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hengrui Medicine Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.